Haematologica (Mar 2009)

A JAK2-V617F activating mutation in addition to KIT and FLT3 mutations is associated with clinical outcome in patients with t(8;21)(q22;q22) acute myeloid leukemia

  • Eisaku Iwanaga,
  • Tomoko Nanri,
  • Naofumi Matsuno,
  • Toshiro Kawakita,
  • Hiroaki Mitsuya,
  • Norio Asou

DOI
https://doi.org/10.3324/haematol.13283
Journal volume & issue
Vol. 94, no. 3

Abstract

Read online

No abstracts available.